ReviewNature clinical practice. Cardiovascular medicine2009
Issues to consider in the pharmaceutical development of a cardiovascular polypill.
Review in Nature clinical practice. Cardiovascular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Long-term efficacy and tolerability of a fixed-dose combination of antihypertensive agents: an open-label surveillance study in China.Clinical drug investigation · 2011Trial
- The Polypill: A New Alternative in the Prevention and Treatment of Cardiovascular Disease.Journal of clinical medicine · 2024Review
- Embedding a Sensitive Liquid-Core Waveguide UV Detector into an HPLC-UV System for Simultaneous Quantification of Differently Dosed Active Ingredients during Drug Release.Pharmaceutics · 2022Article
- Starting Antihypertensive Drug Treatment With Combination Therapy: Controversies in Hypertension - Con Side of the Argument.Hypertension (Dallas, Tex. : 1979) · 2021Article
- The feasibility of polypill for cardiovascular disease prevention in Asian Population.Journal of clinical hypertension (Greenwich, Conn.) · 2021Review
- Challenges and opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals.British journal of clinical pharmacology · 2020Review
- Could patents interfere with the development of a cardiovascular polypill?Journal of translational medicine · 2016Article
- Bisoprolol and bisoprolol-valsartan compatibility studied by differential scanning calorimetry, nuclear magnetic resonance and X-ray powder diffractometry.Pharmaceutical research · 2015Article
- Assessing patterns of use of cardio-protective polypill component medicines in Australian women.Drugs & aging · 2013Article
- Article
- Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles.Bulletin of the World Health Organization · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmaceutical development of a cardiovascular polypill presents several unique challenges. The selection of the type and number of active drugs to be incorporated requires important consideration of clinical, pharmaceutical and commercial issues, and the final decision with regard to the polypill's components depends on how these issues are prioritized. Once the drug combination has been chosen, developers must determine which pharmaceutical formulation should be used. The most appropriate method of drug delivery can vary markedly and depends on the characteristics of the drugs to be combined. Finally, careful consideration of how to gather the type of information required by regulatory agencies before a particular polypill can be approved for use in the general population is crucial. Although the association of multiple, active ingredients in a single dosage form would represent a major step forward in the prevention of cardiovascular conditions, a careful evaluation of all the above-mentioned variables and a well thought-out development plan is mandatory to maximize the chances of success.
Indexed as
Identifiers
19104518What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.